Boston says worst is over with automatic share sell-off
This article was originally published in Clinica
Executive Summary
Boston Scientific saw its share price hit a 52-week low on Friday (October 10) as heavy trading of its stock continued through to the end of the week. A significant portion of the trading was due to the automatic sales of shares owned by the company's co-founders Pete Nicholas and John Abele, and was not a reflection of the company's performance, Boston has stressed. The involuntary sell-off was triggered by recent events, including the bankruptcy of Lehman brothers, caused by the turbulent financial markets. As of the close of market on Friday, around 31 million shares in aggregate has been sold last week through the automatic sell-off. Boston said that they may be additional involuntary selling of the co-founders shares over the next several weeks, but it believes the majority of these sales has already occurred. Boston's share price sunk as low as $6.34 on Friday, before rebounding a little to close at $7.31.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.